The differential gene expression profiles between sensitive and resistant breast cancer cells to adriamycin by cDNA microarray.
OBJECTIVE
Adriamycin is one of the most commonly used drugs in the treatment of breast cancer. This study was performed to understand the molecular mechanisms of drug resistance in breast cancer cells.


METHODS
We have analyzed the MCF-7 breast cell line and its adriamycin-resistant variants, MCF-7/ADR using human 10 K element cDNA microarrays.


RESULTS
We defined 68 genes that were up-regulated (14 genes) or down-regulated (54 genes) in adriamycin resistant breast cancer cells. Several genes, such as G protein-coupled receptor kinase 5, phospholipase A2, guanylate cyclase 1, vimentin, matrix metalloproteinase 1 are up-regulated in drug resistant cells. Several genes, such as interferon, alpha-inducible protein 27, forkhead box M1, mitogen-activated protein kinase 6, regulator of mitotic spindle assembly 1 and tumor necrosis factor superfamily are down-regulated in adriamycin resistant cells. The altered expression of genes observed in microarray was verified by RT-PCR.


CONCLUSIONS
These findings show that cDNA microarray analysis can be used to obtain gene expression profiles reflecting the effect of anticancer drugs on breast cancer cells. Such data may lead to the assigning of signature expression profiles of drug-resistant tumors which may help predict responses to drugs and assist in the design of tailored therapeutic regimens to overcome drug resistance.
Ahn
Myung-Ju
MJ
Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea. ahnmj@hanyang.ac.kr
Lee
Ki-Hwan
KH
Ahn
Joon-Ik
JI
Yu
Dong-Hyun
DH
Lee
Hye-Sook
HS
Choi
Jung-Hye
JH
Jang
Joung Soon
JS
Bae
Jong Min
JM
Lee
Yong-Sung
YS
Biochem Pharmacol. 1998 Aug 15;56(4):451-7
9763220
Anal Biochem. 1983 Mar;129(2):517-21
6303162
Annu Rev Biochem. 1990;59:569-96
2165384
Cancer Res. 2001 Jan 15;61(2):577-81
11212252
Cancer Res. 1991 May 15;51(10):2720-6
1673639
Int J Mol Med. 1998 Feb;1(2):491-4
9852255
Trends Cell Biol. 2000 Sep;10(9):369-77
10932094
Cancer Res. 1989 Jul 15;49(14):3844-8
2544260
Gen Pharmacol. 1996 Mar;27(2):251-5
8919638
Biochem Pharmacol. 2002 Mar 1;63(5):823-31
11911833
Blood. 1999 Mar 1;93(5):1658-67
10029595
Leukemia. 1999 Nov;13(11):1854-8
10557062
J Pharmacol Exp Ther. 2001 Nov;299(2):434-41
11602652
Biochem Biophys Res Commun. 2002 Sep 6;296(5):1125-33
12207890
Annu Rev Biochem. 1988;57:593-625
3052284
Nat Rev Cancer. 2002 Jun;2(6):420-30
12189384
Cancer Res Treat. 2003 Oct;35(5):451-9
26680973
Oncogene. 2001 Mar 15;20(11):1300-6
11313874
Cancer Res. 2000 Aug 1;60(15):4161-6
10945624
Nat Genet. 1996 Dec;14(4):457-60
8944026
Br J Cancer. 1995 Mar;71(3):505-11
7880731
J Bioenerg Biomembr. 1997 Apr;29(2):151-63
9239540
Cancer Res. 1992 Oct 1;52(19):5190-7
1382837
Hum Cell. 2001 Sep;14(3):211-21
11774740
Semin Hematol. 1997 Oct;34(4 Suppl 5):3-8
9408955